The Role of Therapy in the Outcome of Patients with Myelofibrosis

Overview

Journal Cancer

Publisher Wiley

Specialty Oncology

Date 2023 May 27

PMID 37243913

Authors

Lucia Masarova

Prithviraj Bose

Naveen Pemmaraju

Naval G Daver

Koji Sasaki

Helen T Chifotides

Lingsha Zhou

Hagop M Kantarjian

Zeev Estrov

Srdan Verstovsek

Affiliations

Soon will be listed here.

Abstract

Background: The treatment of patients with myelofibrosis (MF) has evolved in the past decade, as reflected in an increased use of various therapeutic agents that could potentially impact patient outcomes.

Methods: In this retrospective study, the authors evaluated the pattern of therapy and its possible impact on the survival of patients with MF at their institution. Patients (n = 802) with newly diagnosed, chronic, overt MF (MF fibrosis grade ≥2, <10% blasts) seen at their cancer center between 2000 and 2020 were included.

Results: Overall, 492 of the included patients (61%) initiated MF-directed therapy during follow-up. The most frequent initial therapy was the JAK inhibitor ruxolitinib (44% of treated patients), investigational agents excluding JAK inhibitors (21%), immunomodulatory agents (18%), other investigational JAK inhibitors (10%), and others (7%). Overall survival was superior for patients who received initial ruxolitinib therapy, with a median survival of 72 months versus approximately 50 months for the remaining approaches, excluding the last group. Thirty-two percent of patients required subsequent therapy (n = 159). The longest survival since the start of second-line therapy was observed in patients who initiated salvage ruxolitinib (median, 35 months; 95% CI, 25-45 months).

Conclusions: This study demonstrated improved outcomes of patients with MF who received treatment with the JAK inhibitor ruxolitinib.

Citing Articles

Association of Myelofibrosis Phenotypes with Clinical Manifestations, Molecular Profiles, and Treatments.

Chifotides H, Verstovsek S, Bose P Cancers (Basel). 2023; 15(13).

PMID: 37444441 PMC: 10340291. DOI: 10.3390/cancers15133331.

References

Luthra R, Patel K, Reddy N, Haghshenas V, Routbort M, Harmon M . Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring. Haematologica. 2013; 99(3):465-73. PMC: 3943309. DOI: 10.3324/haematol.2013.093765. View

Al-Ali H, Griesshammer M, Foltz L, Palumbo G, Martino B, Palandri F . Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts. Br J Haematol. 2020; 189(5):888-903. DOI: 10.1111/bjh.16462. View

Harrison C, Kiladjian J, Al-Ali H, Gisslinger H, Waltzman R, Stalbovskaya V . JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012; 366(9):787-98. DOI: 10.1056/NEJMoa1110556. View

Marcellino B, Verstovsek S, Mascarenhas J . The Myelodepletive Phenotype in Myelofibrosis: Clinical Relevance and Therapeutic Implication. Clin Lymphoma Myeloma Leuk. 2020; 20(7):415-421. DOI: 10.1016/j.clml.2020.01.008. View

Szuber N, Mudireddy M, Nicolosi M, Penna D, Vallapureddy R, Lasho T . 3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. Mayo Clin Proc. 2019; 94(4):599-610. DOI: 10.1016/j.mayocp.2018.08.022. View

Barosi G, Mesa R, Thiele J, Cervantes F, Campbell P, Verstovsek S . Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia. 2007; 22(2):437-8. DOI: 10.1038/sj.leu.2404914. View

Verstovsek S, Gotlib J, Mesa R, Vannucchi A, Kiladjian J, Cervantes F . Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. J Hematol Oncol. 2017; 10(1):156. PMC: 5622445. DOI: 10.1186/s13045-017-0527-7. View

Mascarenhas J, Hoffman R, Talpaz M, Gerds A, Stein B, Gupta V . Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial. JAMA Oncol. 2018; 4(5):652-659. PMC: 5885169. DOI: 10.1001/jamaoncol.2017.5818. View

Mesa R, Komrokji R, Verstovsek S . Ruxolitinib dose management as a key to long-term treatment success. Int J Hematol. 2016; 104(4):420-9. DOI: 10.1007/s12185-016-2084-1. View

10.

Harrison C, Schaap N, Vannucchi A, Kiladjian J, Tiu R, Zachee P . Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. Lancet Haematol. 2017; 4(7):e317-e324. PMC: 8207822. DOI: 10.1016/S2352-3026(17)30088-1. View

11.

Caramazza D, Begna K, Gangat N, Vaidya R, Siragusa S, Van Dyke D . Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients. Leukemia. 2010; 25(1):82-8. PMC: 3035978. DOI: 10.1038/leu.2010.234. View

12.

Pardanani A, Harrison C, Cortes J, Cervantes F, Mesa R, Milligan D . Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial. JAMA Oncol. 2015; 1(5):643-51. DOI: 10.1001/jamaoncol.2015.1590. View

13.

Mesa R, Verstovsek S, Gupta V, Mascarenhas J, Atallah E, Burn T . Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I. Clin Lymphoma Myeloma Leuk. 2015; 15(4):214-221.e1. PMC: 4418454. DOI: 10.1016/j.clml.2014.12.008. View

14.

Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly J, Morra E . New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2008; 113(13):2895-901. DOI: 10.1182/blood-2008-07-170449. View

15.

Vannucchi A, Kantarjian H, Kiladjian J, Gotlib J, Cervantes F, Mesa R . A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica. 2015; 100(9):1139-45. PMC: 4800694. DOI: 10.3324/haematol.2014.119545. View

16.

Masarova L, Bose P, Pemmaraju N, Daver N, Sasaki K, Chifotides H . Improved survival of patients with myelofibrosis in the last decade: Single-center experience. Cancer. 2022; 128(8):1658-1665. DOI: 10.1002/cncr.34103. View

17.

Verstovsek S, Mesa R, Gotlib J, Levy R, Gupta V, Dipersio J . A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012; 366(9):799-807. PMC: 4822164. DOI: 10.1056/NEJMoa1110557. View

18.

Lee B, Moon H, Chae J, Kang K, Kim B, Lee J . Clinical Efficacy of Ruxolitinib in Patients with Myelofibrosis: A Nationwide Population-Based Study in Korea. J Clin Med. 2021; 10(20). PMC: 8540308. DOI: 10.3390/jcm10204774. View

19.

Talpaz M, Paquette R, Afrin L, Hamburg S, Prchal J, Jamieson K . Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts. J Hematol Oncol. 2013; 6(1):81. PMC: 4176265. DOI: 10.1186/1756-8722-6-81. View

20.

Palandri F, Palumbo G, Bonifacio M, Tiribelli M, Benevolo G, Martino B . Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis. Oncotarget. 2017; 8(45):79073-79086. PMC: 5668021. DOI: 10.18632/oncotarget.18674. View